The Gastroenteritis drugs in development market research report provides comprehensive information on the therapeutics under development for Gastroenteritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Gastroenteritis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Gastroenteritis and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Gastroenteritis by ten companies/universities/institutes. The top development phase for Gastroenteritis is preclinical with three drugs in that stage. The Gastroenteritis pipeline has nine drugs in development by companies and one by universities/ institutes. Some of the companies in the Gastroenteritis pipeline products market are: HilleVax, Cocrystal Pharma and Chongqing Zhifei Biological Products.
The key targets in the Gastroenteritis pipeline products market include 5-Hydroxytryptamine Receptor 3, Interleukin 4 Receptor Subunit Alpha, and Interleukin 13.
The key mechanisms of action in the Gastroenteritis pipeline product include Interleukin 13 Inhibitor with one drug in Phase III. The Gastroenteritis pipeline products include four routes of administration with the top ROA being Intramuscular and six key molecule types in the Gastroenteritis pipeline products market including Subunit Vaccine, and Monoclonal Antibody.
Gastroenteritis overview
Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water, and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications.
For a complete picture of Gastroenteritis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
